TM Owner Alexion
Ultomiris 300mg/30ml Injection
Global Shipping : Reliable Global Distribution Network
Express Delivery : Priority Shipping for Every Order
Secure Payments : Trusted Payment Protection System
Disclaimer
Secure Handling
24/7 Worldwide Support
Global Access
Worldwide Access to Health
Cold-Chain Expert
Excellence in Cold-Chain
Trusted Supply
Certified Medical Supply
Indications & Clinical Uses
- Ultomiris (ravulizumab) is a monoclonal antibody directed against complement component C5, indicated for treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).
- Ravulizumab is administered intravenously and provides prolonged complement C5 inhibition for prevention of hemolysis and thrombotic microangiopathy.
- It is particularly valuable for patients intolerant to or inadequately treated by other complement inhibitors.
- Ultomiris represents a long-acting therapeutic option with extended dosing intervals compared to other C5 inhibitors.
Side Effects
- Serious and life-threatening infections are the most significant risk, particularly meningococcal infections; Neisseria meningitidis vaccination is mandatory before treatment initiation.
- Other common infections include respiratory infections and urinary tract infections.
- Hypertension occurs in approximately 20% of patients.
- Headache, nausea, and diarrhea are common gastrointestinal effects.
- Serious adverse reactions include fulminant meningococcemia (even with vaccination), other invasive infections from encapsulated bacteria, and thrombotic microangiopathy progression in some aHUS patients.
- Infusion reactions may occur with initial infusions.
Precautions & Warnings
- BOXED WARNING: Serious meningococcal infections including fulminant sepsis are possible even with meningococcal vaccination.
- Meningococcal vaccination (MenACWY and MenB if available) is REQUIRED at least 2 weeks before Ultomiris initiation; revaccinate per guidelines (typically every 5 years).
- Monitor closely for signs of infection, fever, headache, or neck stiffness—seek immediate medical evaluation.
- Pregnancy category C—use only if benefit justifies fetal risk.
- Monitor complement levels, hemoglobin (PNH), and renal function (aHUS) during treatment.
- Infection risk remains elevated for months after discontinuation.
Avoid Interactions
- No major drug interactions documented with Ultomiris.
- However, other complement inhibitors (eculizumab, pegcetacoplan) should not be used concurrently—overlapping mechanism increases thrombotic risk.
- Live vaccines are contraindicated during complement inhibition due to infection risk; defer non-urgent immunizations.
- Tell your healthcare provider about all medications and supplements.
- Prophylactic antibiotics are often recommended for infection prevention.
- NSAIDs should be used cautiously due to potential renal effects in aHUS patients.
References
Frequently Asked Questions
Ultomiris (ravulizumab) is an intravenous antibody treatment for paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). It blocks complement protein C5 to prevent red blood cell destruction and clotting complications. Ultomiris is given by hospital infusion with long-acting protection.
Ultomiris is administered as an intravenous infusion in a hospital or specialized infusion center. Initial dosing involves loading and maintenance phases, then extended-interval maintenance dosing every 8 weeks after loading. Each infusion must be performed by trained healthcare professionals with emergency equipment available.
Serious meningococcal infection is the most dangerous risk, even in vaccinated patients. Ultomiris carries a boxed warning for this. Other serious infections include those caused by encapsulated bacteria. Fever, severe headache, and neck stiffness require emergency evaluation. Report all signs of infection immediately.
Meningococcal vaccination (MenACWY and MenB) is REQUIRED at least 2 weeks before starting Ultomiris. Revaccinate per guidelines, usually every 5 years. Live vaccines must be avoided during Ultomiris treatment due to infection risk. Ask your provider about other vaccine schedules and timing.
Regular clinic visits monitor hemoglobin levels in PNH and kidney function in aHUS patients. Periodic blood tests check for anemia, platelet counts, and complement levels. Inform your healthcare provider immediately of fever, severe headache, stiff neck, or rash—these signs require emergency evaluation for meningococcal infection.
No, Ultomiris should not be used concurrently with other complement inhibitors like eculizumab or pegcetacoplan due to overlapping mechanisms of action. Using two complement inhibitors together increases the risk of dangerous blood clots and thrombotic microangiopathy. Discuss your current treatments with your healthcare team.
Trusted & Reliable – Your Partner in Global Distribution.
We provide comprehensive lines of pharmaceutical products to support all your healthcare distribution needs.
